Drug intelligence / Profile preview

FC-119

Development stage: Preclinical
Lead developer: Fochon Biosciences
Modality: Small Molecules

Overview

FC-119 is an investigational small molecule therapeutic being developed by Chongqing Fochon Pharmaceutical, a subsidiary of Fosun Pharma. It is currently in the preclinical stage of development, targeting lymphoma and various solid tumors. As an early-stage asset within Fochon's oncology pipeline, the specific biological target and mechanism of action for FC-119 have not been publicly disclosed. The compound represents part of the company's strategic focus on developing targeted small molecule therapies for high-unmet-need cancers.

Beyond the preview

Go deeper on FC-119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FC-119.

Explore the full profile